``We've tried to dismantle this monolithic structure of R&D and create smaller therapeutic areas,'' Kindler, 53, said in an interview with Bloomberg Television. ``There absolutely needs to be more efficiencies in research and development across the industry, and Pfizer is no exception.''
More at Bloomberg
No comments:
Post a Comment